CIA
AMRX icon

Concurrent Investment Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Concurrent Investment Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$741K Sell
59,634
-22,332
-27% -$300K 0.01% 1025
2025
Q4 		$1.03M Buy
81,966
+47,261
+136% +$541K 0.01% 819
2025
Q3 		$347K Buy
+34,705
New +$312K 0.01% 1086

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Concurrent Investment Advisors's AMRX Position: Q1 2026 in Review

Concurrent Investment Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 27% in Q1 2026, selling an estimated $300K and leaving 59,634 shares worth $741K. The position accounts for 0.01% of the portfolio, ranked #1025.

Concurrent Investment Advisors first reported a position in AMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.03M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Concurrent Investment Advisors held 59,634 shares of Amneal Pharmaceuticals worth $741K as of Q1 2026.
  • Concurrent Investment Advisors sold 22,332 Amneal Pharmaceuticals shares in Q1 2026, an estimated $300K.
  • Amneal Pharmaceuticals made up 0.01% of Concurrent Investment Advisors's portfolio in Q1 2026, its #1025 holding.
  • Concurrent Investment Advisors first reported a position in Amneal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Concurrent Investment Advisors's Amneal Pharmaceuticals position peaked at $1.03M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.